Nxera Pharma Collaborates with Tempero Bio on Innovative Treatment
Nxera Pharma Co., Ltd. has exciting news regarding its partnership with Tempero Bio, Inc. The companies are taking significant steps forward in addressing substance use disorders through clinical trials. Tempero Bio has officially initiated a Phase 2 trial for TMP-301, a promising oral treatment that acts as a selective mGluR5 negative allosteric modulator aimed at treating alcohol use disorder.
Details of the Phase 2 Trial
This Phase 2 study is designed to assess the safety and effectiveness of TMP-301 when compared to a placebo in patients suffering from alcohol use disorder. This critical trial marks a pivotal moment in research, potentially offering new hope to those affected by addiction.
Investment in Progress
Tempero Bio has also secured $70 million in financing to support TMP-301’s advancement through the remainder of the Phase 2 trial and explore its efficacy against cocaine use disorder in a subsequent Phase 2 trial. These funds will also assist in crucial Phase 3-enabling activities and preclinical studies addressing additional indications and formulations.
Expert Insights
Matt Barnes, who is the President of Nxera Pharma UK and oversees Research and Development, expressed enthusiasm for the trial's initiation. "We are thrilled to see the progression of TMP-301 as it marks a significant step for our NxWave™ discovery platform. This journey emphasizes our commitment to delivering innovative treatments that cater to urgent medical needs. Our team's efforts this year are expected to yield notable data from various ongoing trials and the commencement of new ones," he stated.
Rising to Meet Unmet Needs
Tempero Bio was founded in 2020 with the specific goal of advancing potent therapies for addiction treatment. The company's portfolio includes TMP-301 and other metabotropic glutamate receptor 5 (mGluR5) NAMs that have the potential to revolutionize the field of substance use disorder therapies. Nxera’s collaboration grants Tempero exclusive global rights to their mGluR5 candidates, reinforcing the strategic alliance.
Looking Ahead with Nxera Pharma
Nxera Pharma, a biotechnology company committed to creating advanced therapies for patients with unmet medical needs, is rapidly advancing its pipeline. The company boasts over 30 active programs designed not only for alcohol and drug use disorders but also for conditions across neurology, gastrointestinal, immunological, metabolic disorders, and rare diseases. Nxera’s proprietary NxWave™ platform empowers cutting-edge drug discovery aimed at producing best-in-class candidates.
Global Presence and Commitment
With over 350 professional staff based in major hubs like Tokyo, Osaka, London, Cambridge, Basel, and Seoul, Nxera employs a diverse range of expertise to tackle significant health challenges on a global scale. Being listed on the Tokyo Stock Exchange under the ticker JPX:4565.T adds to its credibility as a leading force in biopharmaceutical innovation.
Frequently Asked Questions
What is TMP-301?
TMP-301 is a selective mGluR5 negative allosteric modulator developed for treating alcohol use disorder.
Who initiated the Phase 2 trial?
The Phase 2 trial was initiated by Nxera Pharmas's partner, Tempero Bio, Inc.
How many active programs does Nxera Pharma have?
Nxera Pharma has over 30 active programs in various stages of development.
What areas does Nxera Pharma's pipeline focus on?
The pipeline addresses drug use disorders, neurology, gastrointestinal issues, immunology, metabolic disorders, and rare diseases.
Where is Nxera Pharma headquartered?
Nxera Pharma is headquartered in Tokyo, Japan, with additional locations in Osaka, London, Cambridge, Basel, and Seoul.
